drugset / Trial / NCT02468583

Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee

NCT02468583

Phase 2 Terminated 6 enrolled Pacira Pharmaceuticals, Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study was a double-blind, randomized, parallel group, proof of concept study comparing FX006 to Kenalog®-40 (triamcinolone acetonide injectable suspension, USP) in patients with post-traumatic osteoarthritis of the knee.

Timeline

Start
2015-02
Primary completion
2016-07
Completion
2016-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Tafamidis Unknown 32 mg Other
Comparator Triamcinolone Acetonide Other / unclassified 40 mg Other

Indications